Friday 1^st February 2013

14:00      Welcome and introduction (R. Stahel, Zürich)

NSCLC – new techniques (W. Weder)

14:05      PET/CT – new developments (J. Prior, Lausanne)

14:35      Molecular diagnostics: Microchips, genomic sequencing, miRNA or proteomics? (L. Bubendorf, Basel)

15:05      New diagnostic and intervention tools in pulmonology (V. Ninane, Brussels)

15:35      Coffee break

NSCLC – new techniques (M. Pless)

16:00      New developments in surgical techniques (W. Weder, Zürich)

16:30      New developments in radiotherapy (R. Dziadziuszko, Gdansk)

17:00      Case presentations (one case T4 NSCLC and one case thymic carcinoma) (S. Peters / D. Betticher)

17:10      Discussion and preparation of a therapy plan in small groups (2 groups)           

17:35      Presentation of therapy plan and discussion (round table) (S. Peters / D. Betticher)

              Short presentation (5 min) on thymic malignancy:

              -The role of chemotherapy (R. Stahel, Zürich)

              -The role of radiotherapy (R. Dziadziuszko, Gdansk)

              -The role of surgery (W. Weder, Zürich)

18:30      Adjourn

Saturday 2^nd February 2013

Development in targeted therapies (O. Gautschi)

08:00      Chemotherapy and targeted therapies, which, when, why? (D. Betticher, Fribourg)

08:30      Pathways and resistance development in NSCLC carcinomas and their drugs (S. Peters, Lausanne)

09:00      New pathways to be targeted (A. Adjei, Buffalo)

09:30      Coffee break

Targeted therapies in daily practice (D. Betticher)

10:00      Case reports (interactive) (O. Gautschi/M. Pless)

Special situations – sharing thoughts (S. Peters)

11:00      Therapy of pleural effusions, modern techniques (D. Lardinois, Basel)

11:30      Brain metastases and meningitis carcinomatosa, a palliative situation? (R. Dziadziuszko, Gdansk)

12:00      Break

Future developments in NSCLC (R. Stahel)

12:45      Lung cancer screening, ripe for all smokers? (V. Ninane, Brussels)

13:15      The Swiss screening initiative (T. Frauenfelder, Zürich)

13:35      Heterogeneity of NSCLC tumours, the reason for impossible cure? (A. Adjei, Buffalo)

14:05      Wrap-up and conclusions (S. Peters, Lausanne)

14:20      End